India’s drug controller will keep falsified meds out of EU, but GMP standard may be lower
This article was originally published in Scrip
India has confirmed that the Central Drugs Standards Control Organization (CDSCO)/Drugs Controller General of India (DCGI) will be the agency designated to certify active pharmaceutical ingredient (API) exports to the EU. However, GMP equivalence issues have yet to be resolved. Indian industry has suggested that the WHO GMP standard for those ingredients, which differs from the EU GMP standard, would be appropriate. It is not clear that the EU accepts this view.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.